Dr Paul Rees trained in London at St Bartholomew's Hospital Medical College and is a Consultant Interventional Cardiologist and Physician at Barts and the London NHS Trust, one of the largest cardiovascular departments in the UK.  He is also a Surgeon Commander in the Royal Navy.

After qualifying and gaining membership of The Royal College of Physicians, Dr Rees undertook higher medical training in all aspects of cardiology.  He performed 2 years of full time research at the world-leading Hatter Cardiovascular Institute, UCL, studying how to protect the human heart from damage caused during heart attacks, and gained his Doctorate in this field in 2011. 

After completing his research, Dr Paul Rees was then selected for 2 specialist training posts, to train in interventional cardiology in high-volume UK centres. His research interests include acute coronary syndrome cardioprotection, resuscitation, and hypertrophic cardiomyopathy. He has been asked to present research findings and clinical cases at a variety of prestigious international meetings (BCS, ACI, EuroPCR and TCT).  He has a special interest in the management of very complex stent cases, including patients where conventional cardiac surgery would be considered very high-risk.

Dr Rees sees all general cardiology and general medical patients but has a special interest in the assessment of chest pain, coronary angiography,  percutaneous coronary intervention with stenting, and the management of critically ill patients following cardiac arrest.

A stent mounted on a balloon for deployment into a heart artery:

Some recently published research with links:

Early insertion of central lines in the stabilisation of patients suffering from Ebola


Trauma resuscitation using echocardiography in a deployed intensive care unit


Safety and efficacy of percutaneous coronary intervention for unprotected
left main stem disease in a high volume centre


High-dose oral atorvastatin pretreatment of patients undergoing cardiac surgery protects atrial muscle against simulated ischaemia–reperfusion injury

The mitochondrial permeability transition pore as a target for cardioprotection in ventricular cardiomyocytes harvested from patients with obstructive hypertrophic cardiomyopathy

Atorvastatin protects human myocardium from lethal ischaemia-reperfusion injury by activating the risk pathway